2 | 7 | | |
---|
3 | 8 | | |
---|
4 | 9 | | HOUSE CONCURRENT RESOLUTION |
---|
5 | 10 | | WHEREAS, Sickle cell disease is the most common inherited |
---|
6 | 11 | | hemoglobin disorder, but despite its high mortality rates and |
---|
7 | 12 | | severe economic impact, the need for effective therapies remains |
---|
8 | 13 | | unmet; and |
---|
9 | 14 | | WHEREAS, The U.S. Centers for Disease Control and Prevention |
---|
10 | 15 | | estimates that sickle cell disease affects approximately 100,000 |
---|
11 | 16 | | Americans, occurring among about 1 in every 365 African American |
---|
12 | 17 | | births and 1 out of every 16,300 Hispanic American births; and |
---|
13 | 18 | | WHEREAS, Sickle cell disease can affect any organ, including |
---|
14 | 19 | | the kidneys, lungs, and spleen; vaso-occlusive crises are common |
---|
15 | 20 | | among patients, causing recurrent episodes of acute pain and |
---|
16 | 21 | | leading to irreversible end-organ damage, poor quality of life, and |
---|
17 | 22 | | stroke; the life expectancy among sufferers is reduced, tragically, |
---|
18 | 23 | | by some 25 to 30 years; and |
---|
19 | 24 | | WHEREAS, According to a 2018 study, sickle cell disease |
---|
20 | 25 | | imposes a nearly $3 billion economic burden on the U.S. healthcare |
---|
21 | 26 | | system each year, of which 57 percent is attributed to hospital |
---|
22 | 27 | | inpatient costs; more than 70 percent of patients are insured under |
---|
23 | 28 | | state Medicaid programs; and |
---|
24 | 29 | | WHEREAS, The sickle cell disease patient community has long |
---|
25 | 30 | | been medically underserved; in 1972, then-president Richard Nixon |
---|
26 | 31 | | signed the Sickle Cell Anemia Control Act and pledged to end neglect |
---|
27 | 32 | | of the disease, but today, patients still encounter social, |
---|
28 | 33 | | economic, cultural, and geographic barriers to quality care, |
---|
29 | 34 | | including inconsistent treatments, high reliance on emergency care |
---|
30 | 35 | | and public health programs, limited participation in clinical |
---|
31 | 36 | | trials, and lack of access to the limited number of medical |
---|
32 | 37 | | providers with appropriate knowledge and experience; and |
---|
33 | 38 | | WHEREAS, With rapid advancement in such technologies as gene |
---|
34 | 39 | | editing, sickle cell disease stakeholders are working diligently to |
---|
35 | 40 | | expand availability of the transformative therapies that are |
---|
36 | 41 | | currently building clinical momentum; in 2018, the National |
---|
37 | 42 | | Institutes of Health launched the National Heart, Lung, and Blood |
---|
38 | 43 | | Institute Cure Sickle Cell Initiative to accelerate the development |
---|
39 | 44 | | of therapies to cure the disease; at the end of the following year, |
---|
40 | 45 | | the Food and Drug Administration granted accelerated approval for a |
---|
41 | 46 | | new treatment, and it has granted Orphan Drug designation to sickle |
---|
42 | 47 | | cell disease therapies in order to encourage scientific innovation; |
---|
43 | 48 | | and |
---|
44 | 49 | | WHEREAS, The costs of sickle cell disease are enormous in |
---|
45 | 50 | | both human and economic terms, but medical science provides hope of |
---|
46 | 51 | | a long-awaited cure; now, therefore, be it |
---|
47 | 52 | | RESOLVED, That the 87th Legislature of the State of Texas |
---|
48 | 53 | | hereby express support for equitable access to transformative |
---|
49 | 54 | | therapies for sickle cell disease. |
---|